For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

TitleResponses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.
Publication TypeJournal Article
Year of Publication2006
AuthorsMurray HW, Tsai CW, Liu J, Ma X
JournalInfect Immun
Volume74
Issue7
Pagination4370-4
Date Published2006 Jul
ISSN0019-9567
KeywordsAnimals, Female, Genetic Predisposition to Disease, Immunity, Innate, Interferon-gamma, Interleukin-12, Interleukin-18, Interleukin-23, Interleukin-23 Subunit p19, Interleukins, Leishmania donovani, Leishmaniasis, Visceral, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout
Abstract

Interleukin-12 (IL-12) orchestrates acquired resistance in intracellular Leishmania donovani infection in the liver, inducing gamma interferon and, in turn, macrophage activation and parasite killing. Nevertheless, testing in IL-18(-/-) mice compared to wild-type mice and in IL-12p40(-/-) compared to IL-12p35(-/-) mice also suggested both early-acting (IL-18) and late-acting (IL-23) antileishmanial effects independent of IL-12.

DOI10.1128/IAI.00422-06
Alternate JournalInfect Immun
PubMed ID16790814
PubMed Central IDPMC1489747
Grant ListR01 AI045899 / AI / NIAID NIH HHS / United States
AI 16369 / AI / NIAID NIH HHS / United States
AI 45899 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587